Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suncoast Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$28,826,036

4,969 payments

Through program year 2025, Suncoast Research Group LLC is reported as receiving $28,826,036 in research payments, across 4,969 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,232,046 285
2024 Research $8,104,128 367
2023 Research $9,865,528 2,418
2022 Research $6,039,055 1,581
2021 Research $1,542,576 131
2020 Research $509,332 60
2019 Research $1,533,371 127

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $18,183,543 4,249 payments
  2. Bavarian Nordic A/S $4,690,034 70 payments
  3. Pfizer Inc. $1,219,124 97 payments
  4. Ironwood Pharmaceuticals, Inc $1,029,299 22 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,018,016 68 payments
  6. Janssen Research & Development, LLC $1,001,667 22 payments
  7. GlaxoSmithKline, LLC. $873,033 111 payments
  8. Novavax Inc $182,876 15 payments
  9. Gilead Sciences, Inc. $124,655 41 payments
  10. Amgen Inc. $74,759 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $4,690,034 70 payments
  2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $4,426,884 316 payments
  3. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $1,951,664 71 payments
  4. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $1,752,258 13 payments
  5. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $1,535,582 33 payments
  6. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,525,929 646 payments
  7. C3718-302 $1,029,299 22 payments
  8. A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years $1,001,667 22 payments
  9. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $880,536 680 payments
  10. A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age $769,114 554 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record